Jessica Kettell
Psychiatric/Mental Health · Decatur, GANPI 1982320685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$960
- Alkermes, Inc.$609
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$526
- Otsuka America Pharmaceutical, Inc.$506
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,88297%
- Education$2183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 82 | $1,355 |
| Johnson & Johnson | 35 | $1,186 |
| Neurocrine Biosciences, Inc. | 35 | $960 |
| Alkermes, Inc. | 26 | $609 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $526 |
| Otsuka America Pharmaceutical, Inc. | 22 | $506 |
| Axsome Therapeutics, Inc. | 13 | $305 |
| AbbVie | 33 | $304 |
| Supernus Pharmaceuticals, Inc. | 10 | $192 |
| Tris Pharma Inc | 4 | $173 |
| Lundbeck LLC | 8 | $152 |
| E.r. Squibb & Sons, L.L.C. | 6 | $135 |
| Indivior Inc. | 3 | $118 |
| Janssen Scientific Affairs, LLC | 1 | $100 |
| Noven Therapeutics, LLC | 6 | $97 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Bausch Health US, LLC | 3 | $67 |
| Collegium Pharmaceutical, Inc. | 2 | $48 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Sage Therapeutics, LLC | 1 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Acadia Pharmaceuticals Inc | 1 | $26 |
| Biogen | 1 | $23 |
| Merck | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$150
- Dyanavel XR$125
- Quillichew ER$125
- Quillivant$125
- Austedo XR$122
- ABILIFY ASIMTUFII$121
- ABILIFY MAINTENA$121
- INGREZZA$121
- CAPLYTA$116
How this compares
$7,100 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 97 | $697,338 |
| IngrezzaValbenazine Tosylate | 23 | $225,946 |
| NuplazidPimavanserin Tartrate | 12 | $61,135 |
| Invega SustennaPaliperidone Palmitate | 21 | $54,250 |
| Abilify MaintenaAripiprazole | 18 | $48,325 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $41,883 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $28,050 |
| VraylarCariprazine Hcl | 19 | $26,611 |
| Aripiprazole | 133 | $19,383 |
| Lurasidone Hcl | 13 | $6,362 |
| Quetiapine Fumarate | 240 | $6,229 |
| Olanzapine | 138 | $4,706 |
| BelsomraSuvorexant | 11 | $4,597 |
| Duloxetine Hcl | 136 | $4,302 |
| Clomipramine Hcl | 18 | $3,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,355 | $697,33897 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $960 | $225,94623 claims |
| Acadia Pharmaceuticals IncNuplazid | $26 | $61,13512 claims |
| Johnson & JohnsonInvega Sustenna | $1,186 | $54,25021 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $506 | $48,32518 claims |
| Alkermes, Inc.Lybalvi | $609 | $41,88328 claims |
| AbbVieVraylar | $304 | $26,61119 claims |
| MerckBelsomra | $22 | $4,59711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Decatur
- Tina WilliamsDecatur$7K
- Dorcas MwangiDecatur$7K
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.